Cancer Genome Center, Cold Spring Harbor Laboratory, Woodbury, New York; Mount Sinai Liver Cancer Program, Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.
Gastroenterology. 2013 Dec;145(6):1424-35.e1-25. doi: 10.1053/j.gastro.2013.08.055. Epub 2013 Sep 5.
BACKGROUND & AIMS: Epigenetic silencing of tumor suppressor genes contributes to the pathogenesis of hepatocellular carcinoma (HCC). To identify clinically relevant tumor suppressor genes silenced by DNA methylation in HCC, we integrated DNA methylation data from human primary HCC samples with data on up-regulation of gene expression after epigenetic unmasking.
We performed genome-wide methylation analysis of 71 human HCC samples using the Illumina HumanBeadchip27K array; data were combined with those from microarray analysis of gene re-expression in 4 liver cancer cell lines after their exposure to reagents that reverse DNA methylation (epigenetic unmasking).
Based on DNA methylation in primary HCC and gene re-expression in cell lines after epigenetic unmasking, we identified 13 candidate tumor suppressor genes. Subsequent validation led us to focus on functionally characterizing 2 candidates, sphingomyelin phosphodiesterase 3 (SMPD3) and neurofilament, heavy polypeptide (NEFH), which we found to behave as tumor suppressor genes in HCC. Overexpression of SMPD3 and NEFH by stable transfection of inducible constructs into an HCC cell line reduced cell proliferation by 50% and 20%, respectively (SMPD3, P = .003 and NEFH, P = .003). Conversely, knocking down expression of these genes with small hairpin RNA promoted cell invasion and migration in vitro (SMPD3, P = .0001 and NEFH, P = .022), and increased their ability to form tumors after subcutaneous injection or orthotopic transplantation into mice, confirming their role as tumor suppressor genes in HCC. Low levels of SMPD3 were associated with early recurrence of HCC after curative surgery in an independent patient cohort (P = .001; hazard ratio = 3.22; 95% confidence interval: 1.6-6.5 in multivariate analysis).
Integrative genomic analysis identified SMPD3 and NEFH as tumor suppressor genes in HCC. We provide evidence that SMPD3 is a potent tumor suppressor gene that could affect tumor aggressiveness; a reduced level of SMPD3 is an independent prognostic factor for early recurrence of HCC.
肿瘤抑制基因的表观遗传沉默导致肝细胞癌(HCC)的发病机制。为了确定在 HCC 中由 DNA 甲基化沉默的临床相关肿瘤抑制基因,我们将人类原发性 HCC 样本的 DNA 甲基化数据与基因表达上调后去甲基化的数据进行了整合。
我们使用 Illumina HumanBeadchip27K 阵列对 71 个人 HCC 样本进行了全基因组甲基化分析;数据与 4 种肝癌细胞系在暴露于逆转 DNA 甲基化的试剂(去甲基化)后基因再表达的微阵列分析数据相结合。
基于原发性 HCC 的 DNA 甲基化和去甲基化后细胞系中的基因再表达,我们鉴定出 13 个候选肿瘤抑制基因。随后的验证促使我们专注于功能表征 2 个候选基因,即鞘磷脂磷酸二酯酶 3(SMPD3)和神经丝重链(NEFH),我们发现它们在 HCC 中表现为肿瘤抑制基因。通过稳定转染诱导构建物将 SMPD3 和 NEFH 过表达到 HCC 细胞系中,分别使细胞增殖减少 50%和 20%(SMPD3,P =.003 和 NEFH,P =.003)。相反,用小发夹 RNA 敲低这些基因的表达促进了体外细胞侵袭和迁移(SMPD3,P =.0001 和 NEFH,P =.022),并在皮下注射或原位移植到小鼠后增加了它们形成肿瘤的能力,证实了它们在 HCC 中的肿瘤抑制基因作用。在独立的患者队列中,SMPD3 的低水平与根治性手术后 HCC 的早期复发相关(P =.001;风险比= 3.22;95%置信区间:1.6-6.5 在多变量分析中)。
综合基因组分析确定 SMPD3 和 NEFH 为 HCC 的肿瘤抑制基因。我们提供的证据表明,SMPD3 是一种有效的肿瘤抑制基因,可能影响肿瘤的侵袭性;SMPD3 水平降低是 HCC 早期复发的独立预后因素。